EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Effect of a combination of pemafibrate and a mild low‐carbohydrate diet on obese and non‐obese patients with metabolic‐associated fatty liver disease

Yuichiro Suzuki, Shinya Maekawa iD, Kohji Yamashita, Leona Osawa, Yasuyuki Komiyama, Natsuko Nakakuki, Hitomi Takada, Masaru Muraoka, Mitsuaki Sato, Shinichi Takano iD, Mitsuharu Fukasawa iD, Tatsuya Yamaguchi und 4 weitere

Journal of Gastroenterology and Hepatology · 2023

DOI: 10.1111/jgh.16154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Yuichiro Suzuki und 15 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan. Hauptthemen laut MEDLINE: Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Program on Hepatitis of the Japan Agency for Medical Research and Development (AMED) Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Recently, pemafibrate and a low‐carbohydrate diet (LCD) have each been reported to improve fatty liver disease. However, it is unclear whether their combination improves fatty liver disease and is equally effective in obese and non‐obese patients.

Methods

In 38 metabolic‐associated fatty liver disease (MAFLD) patients, classified by baseline body mass index (BMI), changes in laboratory values, magnetic resonance elastography (MRE), and magnetic resonance imaging‐proton density fat fraction (MRI‐PDFF) were studied after 1 year of combined pemafibrate plus mild LCD.

Results

The combination treatment resulted in weight loss ( P = 0.002), improvement in hepatobiliary enzymes (γ‐glutamyl transferase, P = 0.027; aspartate aminotransferase, P < 0.001; alanine transaminase [ALT], P < 0.001), and improvement in liver fibrosis markers (FIB‐4 index, P = 0.032; 7 s domain of type IV collagen, P = 0.002; M2BPGi, P < 0.001). Vibration‐controlled transient elastography improved from 8.8 to 6.9 kPa ( P < 0.001) and MRE improved from 3.1 to 2.8 kPa ( P = 0.017) in the liver stiffness. MRI‐PDFF improved from 16.6% to 12.3% in liver steatosis ( P = 0.007). In patients with a BMI of 25 or higher, improvements of ALT ( r = 0.659, P < 0.001) and MRI‐PDFF ( r = 0.784, P < 0.001) were significantly correlated with weight loss. However, in patients with a BMI below 25, the improvements of ALT or PDFF were not accompanied by weight loss.

Conclusions

Combined treatment with pemafibrate and a low‐carbohydrate diet resulted in weight loss and improvements in ALT, MRE, and MRI‐PDFF in MAFLD patients. Although such improvements were associated with weight loss in obese patients, the improvements were observed irrespective of weight loss in non‐obese patients, indicating this combination can be effective both in obese and non‐obese MAFLD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiverNon-alcoholic Fatty Liver DiseaseHumansButyratesObesityMagnetic Resonance ImagingWeight LossBenzoxazoles

Stichwörter der Autor:innen

MAFLDMREMRI-PDFFlow-carbohydrate diet (LCD)pemafibrate

Substanzen

Butyrates(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidBenzoxazoles

Autor:innen und Institutionen

  • First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
  • Department of Radiology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
  • Department of Radiology, Hamamatsu University School of Medicine, Shizuoka, Japan.

ORCID-Profile: Shinya Maekawa, Shinichi Takano, Mitsuharu Fukasawa, Satoshi Funayama

Förderung

  • Research Program on Hepatitis of the Japan Agency for Medical Research and Development (AMED) Japan

Zitieren

APA

Suzuki, Y., Maekawa, S., Yamashita, K., Osawa, L., Komiyama, Y., Nakakuki, N., Takada, H., Muraoka, M., Sato, M., Takano, S., Fukasawa, M., Yamaguchi, T., Funayama, S., Morisaka, H., Onishi, H., & Enomoto, N. (2023). Effect of a combination of pemafibrate and a mild low‐carbohydrate diet on obese and non‐obese patients with metabolic‐associated fatty liver disease. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16154

Vancouver

Suzuki Y, Maekawa S, Yamashita K, Osawa L, Komiyama Y, Nakakuki N, et al. Effect of a combination of pemafibrate and a mild low‐carbohydrate diet on obese and non‐obese patients with metabolic‐associated fatty liver disease. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16154

BibTeX
@article{Suzuki2023,
  author = {Suzuki, Yuichiro and Maekawa, Shinya and Yamashita, Kohji and Osawa, Leona and Komiyama, Yasuyuki and Nakakuki, Natsuko and Takada, Hitomi and Muraoka, Masaru and Sato, Mitsuaki and Takano, Shinichi and Fukasawa, Mitsuharu and Yamaguchi, Tatsuya and Funayama, Satoshi and Morisaka, Hiroyuki and Onishi, Hiroshi and Enomoto, Nobuyuki},
  title = {Effect of a combination of pemafibrate and a mild low‐carbohydrate diet on obese and non‐obese patients with metabolic‐associated fatty liver disease},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2023},
  doi = {10.1111/jgh.16154}
}
Kostenlos starten →